ClinicalTrials.gg

Program

danicamtiv

Also written as “Danicamtiv” and “MYK-491”.

Its studies are mostly in Cardiomyopathy, Dilated · Heart Failure, led by 2 companies.

Furthest: phase 3, since Feb 14, 20187 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb50 open or runningphase 2since Feb 14, 2018Feb 14, 2018none ahead
Kardigan22 open or runningphase 3since Sep 23, 2025Sep 23, 2025Sep 2027phase 3 · NCT07210723

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2018First study: phase 2 study in Cardiomyopathy, DilatedNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03447990 · 52 enrolled · United States, France, Germany and more
  2. Sep 9, 2020Phase 2 study in Campomelic DysplasiaBristol-Myers Squibb · NCT04572893 · 41 enrolled · United States, Germany, Spain and more
  3. Mar 29, 2023Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT05806359 · 33 enrolled · United States
  4. Jul 11, 2023Phase 1 study in Heart Failure With Reduced Ejection FractionBristol-Myers Squibb · NCT05952089 · 13 enrolled · United States
  5. Aug 31, 2023Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT06027437 · 21 enrolled · United States
  6. Sep 23, 2025Kardigan's first study: phase 3 study in Symptomatic Genetic Dilated CardiomyopathyNew to KardiganKardigan · NCT07210723 · 332 planned · United States, Belgium, Denmark and more
  7. Jul 20, 2026Phase 3 study in Symptomatic Genetic Dilated Cardiomyopathy (DCM)Kardigan · NCT07771465 · 332 planned · United States, Belgium, Denmark and more

Ahead

  1. Sep 2027Primary completion: phase 3 study in Symptomatic Genetic Dilated CardiomyopathyKardigan · NCT07210723
  2. Nov 2032Primary completion: phase 3 study in Symptomatic Genetic Dilated Cardiomyopathy (DCM)Kardigan · NCT07771465

TargetBeta

“Cardiac myosin activator”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
mavacamtenruleBristol-Myers Squibbphase 420
omecamtiv mecarbilruleCytokineticsphase 316

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM) · United States, Belgium, Denmark and more3RecruitingKardiganNov 2032332
NCT07210723Symptomatic Genetic Dilated Cardiomyopathy · United States, Belgium, Denmark and more3RecruitingKardiganSep 2027332
NCT06027437Healthy Volunteers · United States1CompletedBristol-Myers SquibbNov 10, 202321
NCT05952089Heart Failure With Reduced Ejection Fraction · United States1CompletedBristol-Myers SquibbMar 15, 202413
NCT05806359Healthy Volunteers · United States1CompletedBristol-Myers SquibbAug 14, 202333
NCT04572893Campomelic Dysplasia · United States, Germany, Spain and more2TerminatedBristol-Myers SquibbFeb 22, 202441
NCT03447990Cardiomyopathy, Dilated · United States, France, Germany and more2CompletedBristol-Myers SquibbOct 24, 201952

How it is read

Names in the registry

  • “Danicamtiv”, 4 entries
  • “danicamtiv”, 2 entries
  • “MYK-491”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.